Advance Huntington’s disease research with Evotec’s integrated neuroscience capabilities and translational biomarker expertise. Our end-to-end platform supports HTT-lowering and somatic instability programs across in vitro, in vivo, and clinical stages, combining human-relevant models with high-sensitivity immunoassays for precise quantification of mutant and total HTT. With GCP-aligned biomarker analysis, PanOmics integration, and validated HD-specific assays, we enable reliable target engagement, disease monitoring, and data-driven decision-making. Evotec’s comprehensive HD toolbox empowers confident progression from discovery to clinical development, accelerating therapeutic innovation for this complex neurodegenerative disorder.